Hannah Parris, BS

Publications

• Higgins MG, Vemuru S, Helmkamp L, Adams M, Colborn K, Parris H, Huynh V, Christian N, Ahrendt G, Lee C, Kim S, Matlock D, Cumbler E, Tevis S. Access to results of patient reported outcome surveys did not improve longitudinal patient reported outcomes in breast cancer patients in a randomized controlled trial. Am J Surg. 2025 Jan;239:116054. PubMed PMID: 39500006
• Vemuru S, Helmkamp L, Adams M, Colborn K, Parris H, Huynh V, Higgins M, Christian N, Ahrendt G, Baurle E, Lee C, Kim S, Matlock D, Cumbler E, Tevis S. Longitudinal Trends in Patient-Reported Outcomes in the First Year After Lumpectomy Versus Mastectomy. Ann Surg Oncol. 2024 Oct;31(11):7597-7606. PubMed PMID: 39026138
• Mott NM, Huynh V, Vemuru S, Parris HJ, Colborn K, Ahrendt G, Christian N, Kim S, Matlock DD, Cumbler E, Tevis SEA. Barriers and facilitators to measuring patient reported outcomes in an academic breast cancer clinic: An application of the RE-AIM framework. Am J Surg. 2024 Feb;228:180-184. PubMed PMID: 37741803
• Mott NM, Huynh V, Vemuru S, Parris HJ, Colborn K, Ahrendt G, Christian N, Kim S, Matlock DD, Cumbler E, Tevis SEA. Barriers and facilitators to measuring patient reported outcomes in an academic breast cancer clinic: An application of the RE-AIM framework. Am J Surg. 2023 Sep 15. [Epub ahead of print] PubMed PMID: 37741803
• Shagisultanova E, Gradishar W, Brown-Glaberman U, Chalasani P, Brenner AJ, Stopeck A, Parris H, Gao D, McSpadden T, Mayordomo J, Diamond JR, Kabos P, Borges VF. Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR /HER2 Breast Cancer. Clin Cancer Res. 2023 Dec 15;29(24):5021-5030. PubMed PMID: 37363965
• Shagisultanova E, Gao D, Callihan E, Parris HJ, Risendal B, Hines LM, Slattery ML, Baumgartner K, Schedin P, John EM, Borges VF. Overall survival is the lowest among young women with postpartum breast cancer. Eur J Cancer. 2022 Jun;168:119-127. PubMed PMID: 35525161
• Shagisultanova E, Gao D, Callihan E, Parris HJ, Risendal B, Hines LM, Slattery ML, Baumgartner K, Schedin P, John EM, Borges VF. Overall survival is the lowest among young women with postpartum breast cancer. Eur J Cancer. 2022 Jun;168:119-127. PubMed PMID: 35525161
• Borges VF, Hu J, Young C, Maggard J, Parris HJ, Gao D, Lyons TR. Semaphorin 7a is a biomarker for recurrence in postpartum breast cancer. NPJ Breast Cancer. 2020;6:56. PubMed PMID: 33088913